ImmunoGen Inc (IMGN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

ImmunoGen Inc (ImmunoGen) is a clinical-stage biotechnology company that focuses on the development of antibody-drug conjugate therapies for the treatment of cancer. The companys lead product candidate, mirvetuximab soravtansine, a folate receptor alpha (FRa) intended for the treatment of platinum-resistant ovarian cancer and other types of solid tumors, and in Phase 1b/2 testing in combination regimens. Its other pipeline products include IMGN779, a CD33-targeting product candidate for acute myeloid leukemia (AML); and IMGN632 for AML, B-cell acute lymphocytic leukemia, myelodysplastic syndrome and other CD123-positive malignancies. It also carries out early state programs in the areas of solid and liquid tumors. The company has partnership with various pharmaceutical companies to develop and commercialize anticancer compounds. ImmunoGen is headquartered in Waltham, Massachusetts, the US.

ImmunoGen Inc (IMGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 4
List of Figures 4
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ImmunoGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ImmunoGen Inc, Medical Devices Deals, 2012 to YTD 2018 9
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 11
ImmunoGen Enters into Research Agreement with Merck 12
Ventana Medical Systems Enters into Co-Development Agreement with ImmunoGen 13
CytomX Therapeutics Enters Into Co-Development Agreement With ImmunoGen fOR Probody-Drug Conjugates Therapies 14
Licensing Agreements 15
Takeda Enters into Licensing Agreement with ImmunoGen 15
CytomX Therapeutics Exercises Option for Licensing Agreement with ImmunoGen 16
ImmunoGen Enters Into Licensing Agreement With Amgen For TAP Technology 17
Equity Offering 18
ImmunoGen Raises USD150.7 Million in Public Offering of Shares 18
ImmunoGen Raises USD108.4 Million in Public Offering of Shares 20
ImmunoGen Plans to Raise up to USD50 Million in Public Offering 22
ImmunoGen Completes Public Offering Of Common Stock For US$100 Million 23
Debt Offering 25
ImmunoGen Raises USD100 Million in Private Placement of 4.5% Notes Due 2021 25
Asset Transactions 26
Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 26
TPG Special Situations Partner to Acquire Kadcyla Royalty Rights from ImmunoGen for USD200 Million 27
ImmunoGen Inc - Key Competitors 28
ImmunoGen Inc - Key Employees 29
ImmunoGen Inc - Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
May 04, 2018: ImmunoGen Reports Recent Progress and First Quarter 2018 Operating Results 31
Feb 09, 2018: ImmunoGen Reports Pipeline Progress and 2017 Operating Results 33
Nov 03, 2017: ImmunoGen Reports Recent Progress and Third Quarter 2017 Operating Results 35
Jul 28, 2017: ImmunoGen Reports Recent Progress and Second Quarter 2017 Operating Results 37
May 05, 2017: ImmunoGen Reports Recent Progress and First Quarter 2017 Operating Results 39
Feb 17, 2017: ImmunoGen Reports Recent Progress and Operating Results for Six-Month Period and Quarter Ended December 31, 2016 41
Corporate Communications 43
Apr 25, 2018: ImmunoGen Appoints Blaine McKee as Executive Vice President and Chief Business Officer 43
Jan 23, 2017: ImmunoGen Announces Departure of Sandra Poole 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List Of Tables

List of Tables
ImmunoGen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ImmunoGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ImmunoGen Inc, Deals By Therapy Area, 2012 to YTD 2018 8
ImmunoGen Inc, Medical Devices Deals, 2012 to YTD 2018 9
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 11
ImmunoGen Enters into Research Agreement with Merck 12
Ventana Medical Systems Enters into Co-Development Agreement with ImmunoGen 13
CytomX Therapeutics Enters Into Co-Development Agreement With ImmunoGen fOR Probody-Drug Conjugates Therapies 14
Takeda Enters into Licensing Agreement with ImmunoGen 15
CytomX Therapeutics Exercises Option for Licensing Agreement with ImmunoGen 16
ImmunoGen Enters Into Licensing Agreement With Amgen For TAP Technology 17
ImmunoGen Raises USD150.7 Million in Public Offering of Shares 18
ImmunoGen Raises USD108.4 Million in Public Offering of Shares 20
ImmunoGen Plans to Raise up to USD50 Million in Public Offering 22
ImmunoGen Completes Public Offering Of Common Stock For US$100 Million 23
ImmunoGen Raises USD100 Million in Private Placement of 4.5% Notes Due 2021 25
Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 26
TPG Special Situations Partner to Acquire Kadcyla Royalty Rights from ImmunoGen for USD200 Million 27
ImmunoGen Inc, Key Competitors 28
ImmunoGen Inc, Key Employees 29
ImmunoGen Inc, Subsidiaries 30

List Of Figures

List of Figures
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ImmunoGen Inc, Medical Devices Deals, 2012 to YTD 2018 9

ImmunoGen, Inc. - Mergers and Acquisitions (MandA), Partnerships and Alliances and Investment Report

ImmunoGen, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportThe ImmunoGen, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports

USD 350 View Report

ImmunoGen Inc (IMGN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

ImmunoGen Inc (ImmunoGen) is a clinical-stage biotechnology company that focuses on the development of antibody-drug conjugate therapies for the treatment of cancer. The companys lead product candidate, mirvetuximab soravtansine, a

USD 250 View Report

ImmunoGen Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

ImmunoGen Inc Company Profile is a detailed strategic and analytical report on ImmunoGen Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200 View Report

ImmunoGen Inc (IMGN) - Medical Equipment - Deals and Alliances Profile

ImmunoGen Inc (ImmunoGen) is a clinical-stage biotechnology company that focuses on the development of antibody-drug conjugate therapies for the treatment of cancer. The companys lead product candidate, mirvetuximab soravtansine, a

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available